Grand Opening for Drug Product Services

Lonza, a global leader in chemical and biological manufacturing, has celebrated the opening of its pharmaceutical Drug Product Services laboratories in the Stücki Science Park Basel (CH). Scientists in the new 1300 m² facility will focus initially on formulation development, drug product analytical development and quality control. Approximately 75 guests and Lonza participants attended the ribbon-cutting event, which featured a tour of the facility, hands-on experimental stations and a virtual reality journey into the world of Drug Product development, manufacture and administration.

Visiting dignitaries included Christoph Brutschin, State Councillor, Head of the Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt and President of the Conference of the Cantonal Councillors for the Economy (CCCE). He pointed out that Switzerland, and Basel in particular, has a thriving R&D environment: “The new state-of-the-art facility can support not just global, established pharma customers, but also small startups like the ones that make their home in Basel.”

Richard Ridinger, CEO of Lonza, said: “We chose Basel for Lonza’s first-ever drug product development facility because it offers us access to the latest technologies and world-leading experts in a central location, one that’s a hub of innovation in the pharma industry. The addition of drug product development services to Lonza’s global offerings is the next part of our journey along the healthcare continuum, a step that moves us closer to our customers and their patients.”